Brokers Offer Predictions for ImmunityBio FY2028 Earnings

Key Points

• HC Wainwright cut ImmunityBio’s FY2028 earnings estimate to $0.54 per share from $0.60, while keeping a Buy rating and a $15 price target. The firm also projected FY2029 EPS of $0.95 and FY2030 EPS of $1.41.
• ImmunityBio’s latest quarter showed a loss of $0.62 per share, which was worse than the expected loss of $0.08. However, revenue of $44.21 million slightly beat estimates.
• Investor sentiment remains mixed: several analysts still rate the stock positively, but the article notes recent insider selling, active institutional buying, and class-action lawsuit activity tied to FDA and drug-promotion concerns.

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities research analysts at HC Wainwright cut their FY2028 earnings estimates for ImmunityBio in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $0.54 per share for the year, down from their previous forecast of $0.60. HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ImmunityBio's FY2029 earnings at $0.95 EPS and FY2030 earnings at $1.41 EPS.

IBRX has been the topic of several other research reports. The Goldman Sachs Group reissued a "buy" rating on shares of ImmunityBio in a report on Monday, February 23rd. BTIG Research set a $12.00 price target on ImmunityBio in a research note on Friday. D. Boral Capital reiterated a "buy" rating and set a $23.00 price target on shares of ImmunityBio in a research report on Tuesday, May 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of ImmunityBio in a research note on Tuesday, April 14th. Finally, Piper Sandler restated an "overweight" rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of "Moderate Buy" and an average target price of $14.20.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $8.51 on Monday. The company has a 50 day moving average of $8.00 and a 200-day moving average of $5.18. The firm has a market cap of $8.91 billion, a P/E ratio of -10.01 and a beta of 0.02. ImmunityBio has a twelve month low of $1.95 and a twelve month high of $12.43.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to analysts' expectations of $43.07 million.

Insider Buying and Selling

In related news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barry J. Simon sold 75,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director owned 2,850,821 shares of the company's stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 275,000 shares of company stock worth $2,934,500 over the last quarter. Insiders own 69.48% of the company's stock.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently modified their holdings of IBRX. Vanguard Group Inc. raised its position in shares of ImmunityBio by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company's stock worth $64,899,000 after purchasing an additional 5,122,052 shares during the period. State Street Corp lifted its holdings in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company's stock valued at $32,582,000 after purchasing an additional 5,139,890 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of ImmunityBio by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company's stock valued at $15,684,000 after purchasing an additional 1,030,113 shares during the period. Heights Capital Management Inc. acquired a new position in shares of ImmunityBio in the 3rd quarter valued at $16,152,000. Finally, Goldman Sachs Group Inc. increased its stake in ImmunityBio by 439.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company's stock worth $12,182,000 after purchasing an additional 5,012,001 shares in the last quarter. 8.58% of the stock is owned by institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio reported record Q1 2026 results, with net product revenue rising nearly 2.7x year over year to about $44.2 million, and management highlighted continued commercial growth for ANKTIVA. Article: ImmunityBio Reports Record Q1 2026 Results
• Neutral Sentiment: The company’s quarterly loss was larger than expected, but revenue came in above estimates, leaving investors focused more on the growth outlook than the earnings miss. Article: ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate market note said traders are watching a key FDA decision on Anktiva, which could be an important catalyst for the stock but adds regulatory uncertainty. Article: IBRX stock enters heavy catalyst phase
• Negative Sentiment: Multiple law firms are advertising class-action lawsuits and lead-plaintiff deadlines, following allegations that ImmunityBio made misleading statements about Anktiva and drug-promotion claims after an FDA warning letter. Article: IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.